Merck Frosst, Pfizer, Rhone-Poulenc Rorer, Smith-Kline Beecham, Wyeth-Ayerst, YM Biosciences, and Zeneca. Antimicrobial resistance is compromising drug therapy. E. coli remains the predominant ...

Club evenko has lined up three extraordinary Broadway musicals for 2025 at the Place des Arts. This season's package includes ...

This marks Keytruda's first approval for the given indication. Merck (MRK) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.

This week’s quarterly results from Merck looked pretty good, all things considered: Sales and earnings came in ahead of Wall ...

Merck (NYSE: MRK) is a top pharmaceutical company coming off a good quarter that shows it is growing its top and bottom lines. Even with that growth, the stock still trades at a fairly modest ...

Merck booked just under $600 million last year in alliance revenues from the pair, but its attention is now moving to new therapies including sotatercept, a TGF-beta-targeting PAH drug Merck ...

Susan Bowles has received a small grant and has been a speaker for Merck Frosst Canada Ltd. The authors have no other relevant affiliations or financial involvement with any organization or entity ...

A Merck & Co. effort to move its PD-1 behemoth Keytruda into early treatment of lung cancer has reached a dead end, along with another bid to expand into a type of early-stage skin cancer.

Merck & Co.’s best-selling drug Keytruda helped women with a hard-to-treat form of breast cancer live longer, according to the first study to show such a benefit in these patients. After five ...

Merck & Co., Inc. is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...